OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews

Analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report released on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Shares of OPGN stock opened at $1.73 on Monday. The firm’s 50 day moving average is $1.19 and its 200 day moving average is $1.83. OpGen has a 12 month low of $0.53 and a 12 month high of $9.90.
• Five stocks we like better than OpGen
• Breakout Stocks: What They Are and How to Identify Them
• Earn High Dividends With 2 Top REITs Set to Perform in 2025
• Oilfield Leader SLB: An AI Name You Need to Know
• Russell 2000 Index, How Investors Use it For Profitable Trading
• Top ETFs That Beat the Market in 2024 and Could Do It Again

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Receive News & Ratings for OpGen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OpGen and related companies with MarketBeat.com’s FREE daily email newsletter.…Read more by Defense World Staff